26.Aug.2022 | Acquisition of shares of Prestige Biologics | Prestige Biopharma Limited |
24.Aug.2022 | PBP1510 patent registration in Singapore | Prestige Biopharma Limited |
12.Aug.2022 | More than 30% change in sales or profit and loss structure for FY2022 as compared to FY20221
| Prestige Biopharma Limited |
24.Mar.2022 | Final Clinical Study Report (CSR) of the Phase 3 Study of HD201 (Trastuzumab, Tuznue®) | Prestige Biopharma Limited |
25.Feb.2022 | Half-year Report (FY2022, Q2) | Prestige Biopharma Limited |
17.Feb.2022 | Approval for PBP1510 Clinical Trial (Phase 1/2a) in Spain | Prestige Biopharma Limited |
28.Jan.2022 | Decision on paid-up capital increase of PBP Korea (USD 45 million) | Prestige Biopharma Limited |
27.Jan.2022 | Acquisition of Patent Rights for ‘Antibody specifically binding to PAUF and use thereof’ in Japan
| Prestige Biopharma Limited |
27.Dec.2021 | Results of the Extraordinary General Meeting | Prestige Biopharma Limited |
17.Dec.2021 | Decision to Make an Equity Investment on PBP Korea (USD 90 million) | Prestige Biopharma Limited |
09.Dec.2021 | Notice of the Extraordinary General Meeting | Prestige Biopharma Limited |
09.Dec.2021 | Board Resolution to call the Extraordinary General Meeting | Prestige Biopharma Limited |
09.Dec.2021 | Decision to make a cash loan to Prestige Biologics Co., Ltd. (USD 110 million) | Prestige Biopharma Limited |
09.Dec.2021 | Supply and Commercialization Agreement with Dr. Reddy for HD201 (Trastuzumab biosimilar) | Prestige Biopharma Limited |
03.Dec.2021 | Report on Stocks Held in Bulk / Report on Status of Specific Securities Owned by Executive Officers, etc. | Octava Fund Limited |
03.Dec.2021 | Report on Changes in Equity Shares of the Largest Shareholder | Octava Fund Limited |
29.Nov.2021 | Quarterly Report (FY2022, Q1) | Prestige Biopharma Limited |
29.Nov.2021 | Contract Manufacturing Agreement with Enso and Stelis | Prestige Biopharma Limited |
17.Nov.2021 | Other Management Information(Voluntary Disclosure)(Public announcement of the setting of the reference date for the depository receipt for the confirmation of the shareholders of rights at the extraordinary meeting of shareholders)
| Prestige Biopharma Limited |
15.Nov.2021 | Confirmation to Grant Voting Rights as of 30/November/2021 for EGM (Extraordinary General Meeting)
| Prestige Biopharma Limited |
24.Sep.2021 | Appointment or Dismissal of Outside Directors (Reappointment of Prof. Bang Kue Ho)
| Prestige Biopharma Limited |
24.Sep.2021 | Results of the 6th Annual General Meeting | Prestige Biopharma Limited |
16.Sep.2021 | Annual Report (FY2021) | Prestige Biopharma Limited |
15.Sep.2021 | [Correction] Notice of the 6th Annual General Meeting
| Prestige Biopharma Limited |
15.Sep.2021 | [Correction] Board Resolution to call the 6th Annual General Meeting | Prestige Biopharma Limited |
10.Sep.2021 | Submission of Audit Report | Prestige Biopharma Limited |
9.Sep.2021 | [Correction] Decision to Make a Cash Loan to PBP Korea (KRW 61,490 million) - schedule change | Prestige Biopharma Limited |
12.Aug.2021 | Reporting of Sales, Operating income/loss or Net income/loss Changes by 30% or more | Prestige Biopharma Limited |
12.Aug.2021 | [Correction] Quarterly Report (FY2021, Q3) | Prestige Biopharma Limited |
21.July.2021 | Acquisition of patent rights for ‘Method for preparing antibody through regulation of sugar content of antibody’ in Europe | Prestige Biopharma Limited |
18.June.2021 | Approval for PBP1510 clinical trial (Phase 1/2a) in France | Prestige Biopharma Limited |
15.June.2021 | Confirmed list of shareholders & voting rights as of 30/June/2021 for shareholders’ meeting | Prestige Biopharma Limited |
28.May.2021 | Decision to make an equity investment on PBP Korea | Prestige Biopharma Limited |
26.May.2021 | Acquisition of patent rights for ‘Antibody specifically binding to PAUF and use thereof’ in USA | Prestige Biopharma Limited |
24.Feb.2021 | Change of KOSPI stock name | Prestige Biopharma Limited |
18.Feb.2021 | Report on status of specific securities owned by executive officers | Bang Kyuho |
16.Feb.2021 | Report on stocks held in bulk | Octava Fund Limited |
16.Feb.2021 | Report on status of specific securities owned by executive officers | Octava Fund Limited |
16.Feb.2021 | Report on changes in equity shares of the largest shareholder | Prestige Biopharma Limited |
15.Feb.2021 | Report on status of specific securities owned by executive officers | Jeon Kyunghee |
15.Feb.2021 | Report on status of specific securities owned by executive officers | Michael Jinwoo Kim |
15.Feb.2021 | Report on status of specific securities owned by executive officers | Park Soyeon |
15.Feb.2021 | Report on status of specific securities owned by executive officers | Mayson Partners |
15.Feb.2021 | Report on stocks held in bulk | Mayson Partners |
28.Jan.2021 | Report on results of issuance of securities | Prestige Biopharma Limited |
22.Jan.2021 | Prospectus | Prestige Biopharma Limited |
22.Jan.2021 | Securities registration statement (IPO) | Prestige Biopharma Limited |
